Accurate diagnosis of cardiovascular involvement in systemic lupus erythematosus (SLE) remains challenging, due to limitations of echocardiography. We hypothesized that cardiovascular magnetic resonance can detect cardiac lesions missed by echocardiography in SLE patients with atypical symptoms.
Aim
To use cardiovascular magnetic resonance in SLE patients with atypical symptoms and investigate the possibility of silent heart disease, missed by echocardiography.
Patients/methods
From 2005 to 2015, 80 SLE patients with atypical cardiac symptoms/signs (fatigue, mild shortness of breath, early repolarization and sinus tachycardia) aged 37 ± 6 years (72 women/8 men), with normal echocardiography, were evaluated using a 1.5 T system. Left and right ventricular ejection fractions, T2 ratio (oedema imaging) and late gadolinium enhancement (fibrosis imaging) were assessed. Acute and chronic lesions were defined as late gadolinium enhancement-positive plus T2>2 and T2<2, respectively. Lesions were characterized according to late gadolinium enhancement patterns as: diffuse subendocardial, subepicardial and subendocardial/transmural, due to vasculitis, myocarditis and myocardial infarction, respectively.
Results
Abnormal cardiovascular magnetic resonance findings were identified in 22/80 (27.5%) of SLE patients with normal echocardiography, including 4/22 with recent silent myocarditis, 5/22 with past myocarditis (subepicardial scar in inferolateral wall), 9/22 with past myocardial infarction (six inferior and three anterior subendocardial infarction) and 4/22 with diffuse subendocardial fibrosis due to vasculitis. No correlation between cardiovascular magnetic resonance findings and inflammatory indices was identified.
Conclusions
Cardiovascular magnetic resonance in SLE patients with atypical cardiac symptoms/signs and normal echocardiography can assess occult cardiac lesions including myocarditis, myocardial infarction and vasculitis that may influence both rheumatic and cardiac treatment.
TanEMCohenASFriesJF. The 1982 revised criteria for the classification of systemic lupus erythmatosus. Arthritis Rheum1982; 25: 1271–1277.
2.
PinaFPSilvaGJMartinsRPPaivaNABonfiglioliRProvenzaJR. Early cardiac involvement in systemic lupus erythematosus. Rev Cienc Med2003; 12: 381–385.
3.
MavrogeniSKarabelaGStavropoulosEet al.Heart failure imaging patterns in systemic lupus erythematosus. Evaluation using cardiovascular magnetic resonance. Int J Cardiol2014; 176: 559–561.
4.
MavrogeniSSfikakisPPGialafosEet al.Cardiac tissue characterization and the diagnostic value of cardiovascular magnetic resonance in systemic connective tissue diseases. Arthritis Care Res (Hoboken)2014; 66: 104–112.
5.
TanEMCohenASFriesJFet al.The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271–1277.
6.
VitaliCBencivelliWIsenbergDAet al.Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol1992; 10: 541–547.
7.
MavrogeniSBratisKKolovouG. Pathophysiology of Q waves in II, III, avF in systemic lupus erythematosus. Evaluation using cardiovascular magnetic resonance imaging. Lupus2012; 21: 821–829.
8.
WheltonPK. Epidemiology of hypertension. Lancet1994; 344: 101–106.
9.
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143–3421.
10.
National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes1979; 28: 1039–1057.
11.
Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269: 3015–3023.
12.
ChobanianAVBakrisGLBlackHRet al.The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA2003; 289: 2560–2572.
13.
ZvolenskyMJBernsteinACardenasSJColotlaVAMarshallECFeldnerMT. Anxiety sensitivity and early relapse to smoking: a test among Mexican daily, low-level smokers. Nicotine Tobacco Res2007; 9: 483–491.
14.
Bellenger NG, Pennell DJ. Ventricular function. In: Manning WJ, Pennell DJ (eds) Cardiovascular Magnetic Resonance. New York: Churchill Livingstone, 2002, pp. 99–111.
15.
GrothuesFSmithGCMoonJCet al.Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol2002; 90: 29–34.
16.
GrothuesFMoonJCBellengerNGSmithGSKleinHUPennellDJ. Interstudy reproducibility of right ventricular volumes, function and mass with cardiovascular magnetic resonance. Am Heart J2004; 147: 218–223.
17.
MaceiraAMPrasadSKKhanMPennellDJ. Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson2006; 8: 417–426.
18.
Abdel-AtyHBoyePZagrosekAet al.Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol2005; 45: 1815–1822.
19.
KimRJFienoDSParrishTBet al.Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation1999; 100: 1992–2002.
20.
FriedrichMGSechtemUSchulz-MengerJet al.International Consensus Group on Cardiovascular Magnetic Resonance in Myocarditis. Cardiovascular magnetic resonance in myocarditis: a JACC White Paper. J Am Coll Cardiol2009; 53: 1475–1487.
21.
RobbersLFBaarsENBrouwerWPet al.T1 mapping shows increased extracellular matrix size in the myocardium due to amyloid depositions. Circ Cardiovasc Imaging2012; 5: 423–426.
22.
MyungGForbessLJIshimoriMLChughSWallaceDWeismanMH. Prevalence of resting-ECG abnormalities in systemic lupus erythematosus: a single-center experience. Clin Rheumatol2017; 36: 1311–1316.
23.
Al RayesHHarveyPJGladmanDDet al.Prevalence and associated factors of resting electrocardiogram abnormalities among systemic lupus erythematosus patients without cardiovascular disease. Arthritis Res Ther2017; 19: 31–31.
24.
Bourré-TessierJUrowitzMBClarkeAEet al.Electrocardiographic findings in systemic lupus erythematosus: data from an international inception cohort. Arthritis Care Res (Hoboken)2015; 67: 128–135.
25.
MavrogeniSMarkousis-MavrogenisGKoutsogeorgopoulouLet al.Cardiovascular magnetic resonance imaging pattern at the time of diagnosis of treatment naïve patients with connective tissue diseases. Int J Cardiol.. Epub ahead of print 1 February 2017 pii: S0167-5273(16)33153-9.
26.
ZhangYCorona-VillalobosCPKianiANet al.Myocardial T2 mapping by cardiovascular magnetic resonance reveals subclinical myocardial inflammation in patients with systemic lupus erythematosus. Int J Cardiovasc Imaging2015; 31: 389–397.
27.
PuntmannVOD’CruzDSmithZet al.Native myocardial T1 mapping by cardiovascular magnetic resonance imaging in subclinical cardiomyopathy in patients with systemic lupus erythematosus. Circ Cardiovasc Imaging2013; 6: 295–301.
28.
SinghJAWoodardPKDávila-RománVGet al.Cardiac magnetic resonance imaging abnormalities in systemic lupus erythematosus: a preliminary report. Lupus2005; 14: 137–144.
29.
ThomasGCohen AubartFChicheLet al.Lupus myocarditis: initial presentation and longterm outcomes in a multicentric series of 29 patients. J Rheumatol2017; 44: 24–32.
30.
MavrogeniSBratisKSfendourakiEPapadopoulouEKolovouG. Myopericarditis, as the first sign of rheumatoid arthritis relapse, evaluated by cardiac magnetic resonance. Inflamm Allergy Drug Targets2013; 12: 206–211.
31.
UrowitzMBGladmanDDAndersonNMet al.Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort. Lupus Sci Med2016; 3: e000143–e000143.
32.
Aviña-Zubieta JA, To F, Vostretsova K, De Vera M, Sayre EC, Esdaile JM. Risk of myocardial infarction and stroke in newly diagnosed systemic lupus erythematosus: a general population-based study. Arthritis Care Res (Hoboken). Epub ahead of print 27 January 2017. DOI: 10.1002/acr.23018.
33.
Hermansen ML, Lindhardsen J, Torp-Pedersen C, Faurschou M, Jacobsen S. The risk of cardiovascular morbidity and cardiovascular mortality in systemic lupus erythematosus and lupus nephritis: a Danish nationwide population-based cohort study. Rheumatology (Oxford). Epub ahead of print 3 January 2017. pii: kew475. DOI: 10.1093/rheumatology/kew475.
34.
GonçalvesLFSoutoFMFaroFNOliveiraJLBarreto-FilhoJASousaAC. Biventricular thrombus and endomyocardial fibrosis in antiphospholipid syndrome. Arq Bras Cardiol2012; 99: e162–e165.
35.
MavrogeniSISfikakisPPKitasGDKolovouGTektonidouMG. Cardiac involvement in antiphospholipid syndrome: the diagnostic role of noninvasive cardiac imaging. Semin Arthritis Rheum2016; 45: 611–616.
36.
YuXHLiYN. Echocardiographic abnormalities in a cohort of Chinese patients with systemic lupus erythematosus – a retrospective analysis of eighty-five cases. J Clin Ultrasound2011; 39: 519–526.
37.
MillerAMMcInnesIB. Cytokines as therapeutic targets to reduce cardiovascular risk in chronic inflammation. Curr Pharm Des2011; 17: 1–8.
38.
HuntSAAbrahamWTChinMHet al.American College of Cardiology Foundation; American Heart Association. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in Collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol2009; 53: e1–e90.
39.
LinCYShihCCYehCCChouWHChenTLLiaoCC. Increased risk of acute myocardial infarction and mortality in patients with systemic lupus erythematosus: two nationwide retrospective cohort studies. Int J Cardiol2014; 176: 847–851.
40.
LealGNSilvaKFLianzaACet al.Subclinical left ventricular dysfunction in childhood-onset systemic lupus erythematosus: a two-dimensional speckle-tracking echocardiographic study. Scand J Rheumatol2016; 45: 202–209.
